Vaccines

Therapeutic Areas

 

shutterstock_360472571 

Several diseases are characterized by an overproduction of cytokines. This overproduction is responsible for autoimmune, inflammatory diseases, allergies and certain types of cancers.  The specificity of Neovacs Kinoid® technology makes cytokines immunogenic when they are not naturally – a revolutionary therapeutic innovation that provides an important treatment opportunity in the fields of autoimmune and inflammatory diseases. Today, the company is focusing its development efforts on offering patients new therapeutic options based on its Kinoid® vaccines.

 

IFNα KINOID AND LUPUS

SYSTEMIC LUPUS ERYTHEMATOSUS(SLE) OR LUPUS ERYTHEMATOSUS DISSEMINATED (LED)

Systemic lupus erythematosus (SLE) or lupus erythematosus is a debilitating, chronic autoimmune disease whose etiology remains unknown. SLE is characterized by a loss of tolerance of self-antigens, with the production of autoantibodies, especially antinuclear antibodies that attack healthy tissues and cause inflammatory reactions in different parts of the body. The disease can affect multiple organs (skin, kidneys, joints, heart, lungs, central nervous system, etc. ) and is characterized by heterogeneous clinical signs (skin rashes, arthritis, photosensitivity, nephritis, neurological disorders, anemia, thrombocytopenia, etc.), which vary from one person to another and change during the progression of the disease. Systemic lupus erythematosus affects mostly women.

 

EPIDEMIOLOGY OF SYSTEMIC LUPUS ERYTHEMATOSUS

 

  • the overall annual incidence reached 3.32 cases per 100,000 people
  • the disease affects mostly women. (9 women/1 man)
  • the disease is mainly diagnosed in patients aged between 15 to 45 years.

In its successfully completed Phase I/IIa clinical study in lupus, Neovacs has already demonstrated that anti-interferon antibodies have a biological activity capable of neutralizing the IFNα signature in Systemic Lupus Erythematous (SLE) patients immunized with IFNα kinoid.  In addition, the treatment is well tolerated with a long lasting immune response. (Lauwerys Arthritis&Rheum 2013 and Ducreux 2016 Rheumatology)

Find more information about the main results of this study on the European Register for clinical trials www.clinicaltrialsregister.eu and also on clinicaltrials.gov

 

 

IL-4/ IL-13 KINOID, TO TREAT ALLERGIES

These preclinical works conducted in collaboration with Dr. Laurent Reber from the research team Inserm Unit 1222, Institut Pasteur, have been presented during several major scientific conferences.It has been demonstrated in a representative allergic asthma model that a treatment with IL-4 / IL-13 Kinoid enhanced the production of polyclonal antibodies, which neutralize the two targeted cytokines IL-4 and IL-13, both being development factors for allergic asthma, thus avoiding the occurrance of any symptoms.

Why should you invest in Neovacs ?

Go to the investors section